Skip to main content

Table 3 Patients’ characteristics association with the cf-nDNA and the relative cf-mtDNA (cf-ND1/cf-β-globin ratio) levels in individual human follicular fluid

From: Cell-free mitochondrial DNA in human follicular fluid: a promising bio-marker of blastocyst developmental potential in women undergoing assisted reproductive technology

Variable Mean n (%) Min-Max SD cf-nDNA relative cf-mtDNA
β ± SE p β ± SE p
Age (years) 32.13 225 (100) 21–45 4.85 −0.034 ± 0.03 0.25 0.22 ± 0.085 0.009
BMI (kg/m2) 22.38 225 (100) 16.6–33.9 3.58 0.069 ± 0.044 0.12 −0.15 ± 0.13 0.25
AMH (ng/ml) 3.37 219 (97.3) 0.33–8.67 1.99 0.0007 ± 0.075 0.70 0 ± 0.20 0.89
Basal FSH (IU/L) 7.49 225 (100) 1.79–17.52 2.60 0.025 ± 0.057 0.66 −0.27 ± 0.16 0.09
Basal LH (IU/L) 4.45 225 (100) 0.51–21.41 2.49 0.001 ± 0.059 0.25 0.016 ± 0.17 0.61
Basal E2 (pg/ml) 43.56 225 (100) 6–299.8 39.24 0 ± 0.004 0.88 0.006 ± 0.010 0.26
Antral follicle count 17.48 225 (100) 3–40 7.84 0.026 ± 0.017 0.012 −0.050 ± 0.053 0.34
Days of stimulation 9.75 225 (100) 3–22 2.74 −0.019 ± 0.05 0.039 0.0023 ± 0.15 0.48
Total dose of gonadotropins (IU) 2089.69 225 (100) 225–6800 835.12 −0.027 ± 0.0002 0.015 0.0014 ± 0.0005 0.58
Ultra-long protocol 97 (43.11)     ref
Long protocol 17 (7.56) 0.054 ± 0.57 0.96 −1.56 ± 1.64 0.34
Antagonist protocol 71 (31.56) 0.17 ± 0.34 0.63 −0.18 ± 0.98 0.86
PPOS 40 (17.78) −0.37 ± 0.41 0.36 1.33 ± 1.17 0.26
  1. Data are presented as means ±standard deviation (SD). β ± SE, regression coefficient ± standard error. P-values is the result of linear mixed models. Statistical significance was assumed at P < 0.05.BMI, body mass index. FSH follicle-stimulating hormone, LH luteinizing hormone, E2 17β-estradiol, AMH anti-Müllerian hormone, PPOS progestin-primed ovarian stimulation